Skip to main content
SpringerLink
Log in

Medikamentöse Behandlung des Uterus myomatosus

  • Chapter
Uterus myomatosus

  • 36 Accesses

Zusammenfassung

Die endokrine Behandlung des Uterus myomatosus ist naheliegend. Myome entstehen in der fertilen Phase der Frau unter Hormoneinfluss und verlieren häufig an Bedeutung in der Menopause. Eine ganze Reihe von endokrinen Ansatzpunkten ist denkbar (s. Übersicht). GnRH-Analoga wurden lange Zeit in der endokrinen Behandlung favorisiert. Sie gehörten zu »multimodalen« Therapiekonzepten. Eine Vorbehandlung vor operativer Intervention war fast obligat. Heute wird ihre Bedeutung jedoch nicht mehr so wertig gesehen. Im Folgenden soll das Spektrum der medikamentösen Behandlungsmöglichkeiten des Uterus myomatosus kompakt dargestellt werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Benagiano G, Kivinen ST, Fadini R, Cronje H, Klintorp S, van der Spuy ZM (1996) Zoladex (goserelin acetate) and the anemic patient: results of a multicenter fibroid study. Fertil Steril 66(2): 223–229

    PubMed  CAS  Google Scholar 

  • Bianchi S, Fedele L, Vignali M, Galbiati E, Cherubini R, Ortolani S (1995) Effects an bone mineral density of 12-month goserelin treatment in over 40-year-old women with uterine myomas. Calcif Tissue Int 57(1): 78–80

    Article  PubMed  CAS  Google Scholar 

  • Branham WS, Fishman R, Streck RD, Medlock KL, De George JJ, Sheehan DM (1996) ICI 182,780 inhibits endogenous estrogen-dependent rat uterine growth and tamoxifen-induced developmental toxicity. Biol Reprod 54(1): 160–167

    Article  PubMed  CAS  Google Scholar 

  • Brosens I, Deprest J, Dal Cin P, Van den Berghe H (1998) Clinical significance of cytogenetic abnormalities in uterine myomas. Fertil Steril 69(2): 232–235

    Article  PubMed  CAS  Google Scholar 

  • Burroughs KD, Kiguchi K, Howe SR, Fuchs-Young R, Trono D, Barrett JC, Walker C (1997) Regulation of apoptosis in uterine leiomyomata. Endocrinology 138(7): 3056–3064

    Article  PubMed  CAS  Google Scholar 

  • Coutinho EM, Goncalves MT (1989) Long-term treatment of leiomyomas with gestrinone. Fertil Steril 51(6): 939–946

    PubMed  CAS  Google Scholar 

  • Demopoulos RI, Jones KY, Mittal KR, Vamvakas EC (1997) Histology of leiomyomata in patients treated with leuprolide acetate. Int J Gynecol Pathol 16(2): 131–137

    Article  PubMed  CAS  Google Scholar 

  • Dilts PV Jr, Hopkins MP, Chang AE, Cody RL (1992) Rapid growth of leiomyoma in patient receiving tamoxifen. Am J Obstet Gynecol 166: 167–168

    PubMed  Google Scholar 

  • Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C (1996) A controlled trial of raloxifene (LY139481) HCI: impact an bone turnover and serum lipid profìle in healthy postmenopausal women. J Bone Miner Res 11(6): 835–842

    Article  PubMed  CAS  Google Scholar 

  • Dukes M, Waterton JC, Wakeling AE (1993) Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging. J Endocrinol 138(2): 203–210

    Article  PubMed  CAS  Google Scholar 

  • Felberbaum RE, Germer U, Ludwig M et al. (1998) Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Hum Reprod 13(6): 1660–1668

    Article  PubMed  CAS  Google Scholar 

  • Fruscella L, Ciaglia EM, Danti M, Fiumara D (1997) Vitamin E in the treatment of pregnancy complicated by uterine myoma. Minerva Ginecol 49(4): 175–179

    PubMed  CAS  Google Scholar 

  • Fuchs-Young R, Howe S, Hale L, Miles R, Walker C (1996) Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Mol Carcinog 17(3): 151–159

    Article  PubMed  CAS  Google Scholar 

  • Gerris J, Degueldre M, Peters AA, Romao F, Stjernquist M, al-Taher H (1996) The place of Zoladex in deferred surgery for uterine fibroids. Zoladex Myoma Study Group. Horm Res 45(6): 279–284

    Article  PubMed  CAS  Google Scholar 

  • Gonzalez-Barcena D, Alvarez RB, Ochoa EP et al. (1997) Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod 12(9): 2028–2035

    Article  PubMed  CAS  Google Scholar 

  • Hackenberg R, Gesenhues T, Deichert U, Duda V, Schmidt-Rhode P, Schulz KD (1992) The response of uterine fibroids to GnRH-agonist treatment can be predicted in most cases after one month. Eur J Obstet Gynecol Reprod Biol 45(2): 125–129

    Article  PubMed  CAS  Google Scholar 

  • Harrison-Woolrych ML, Chamock-Jones DS, Smith SK (1994) Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction. J Clin Endocrinol Metab 78(5): 1179–1184

    Article  PubMed  CAS  Google Scholar 

  • Healy DL, Burger HG (1977) Review: human prolactin-recent advances in physiology and therapy. Aust N Z J Obstet Gynaecol 17(2): 61–78

    Article  PubMed  CAS  Google Scholar 

  • Howe SR, Gottardis MM, Everitt JI, Walker C (1995) Estrogen Stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology 136(11): 4996–5003

    Article  PubMed  CAS  Google Scholar 

  • Kedar RP, Boume TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S (1994) Effects of tamoxifen an uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343(8909): 1318–1321

    Article  PubMed  CAS  Google Scholar 

  • Le Bouedec G, de Latour M, Dauplat J (1995) Expansive uterine myoma during tamoxifen therapy. 11 cases. Presse Med 24(36): 1694–1696

    PubMed  Google Scholar 

  • Liehr JG, Ricci MJ, Jefcoate CR, Hannigan EV, Hokanson JA, Zhu BT (1995) 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci USA 92(20): 9220–9224

    Article  PubMed  CAS  Google Scholar 

  • Lumsden MA, West CP, Hillier H, Baird DT (1989) Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin)-lack of shrinkage of uterine fibroids. Fertil Steril 52(6): 924–929

    PubMed  CAS  Google Scholar 

  • Mettler L, Mayer-Eichenberger D, Kienle E, Lipka K (1993) Leuprorelinacetat-Depot zur Behandlung des Uterus myomatosus. Fertilität 9: 167–174

    Google Scholar 

  • Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS (1993) Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 76(2): 513–517

    Article  PubMed  CAS  Google Scholar 

  • O’Reilly MS (1997) Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS 79: 273–294

    PubMed  Google Scholar 

  • Rutgers JL, Spong CY, Sinow R, Heiner J (1995) Leuprolide acetate treatment and myoma arterial size. Obstet Gynecol 86(3): 386–388

    Article  PubMed  CAS  Google Scholar 

  • Sadan O, van Iddekinge B, van Gelderen CJ, Savage N, Becker PJ, van der Walt LA, Robinson M (1987) Oestrogen and progesterone reeeptor concentrations in leiomyoma and normal myometrium. Ann Clin Biochem 24: 263–267

    PubMed  Google Scholar 

  • Schlaff WD, Zerhouni EA, Huth JA, Chen J, Damewood MD, Rock JA (1989) A placebo-controlled trial of a depot gonadotropinreleasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. Obstet Gynecol. 74(6): 856–862

    PubMed  CAS  Google Scholar 

  • Sun L (1995) 38 cases of hysteromyoma treated with tumor-resolving decoction. J Tradit Chin Med 15(4): 273–276

    PubMed  CAS  Google Scholar 

  • Surrey ES (1995) Steroidal and nonsteroidal »add-back« Therapy: extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynaecologic patient. Fertil Steril 64(4): 673–685

    PubMed  CAS  Google Scholar 

  • Stolz W, Pfutzenreuter N (1997) Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect an leiomyoma volume and operability. German Leuprorelin Study Group. Zentralbl Gynakol 119(10): 468–475

    PubMed  CAS  Google Scholar 

  • Thomas EJ, Walton PL, Thomas NM, Dowsett M (1994) The effect of ICI 182,780, a pure antioestrogen, an the hypothalamic-pituitary-gonadal axis and an endometrial proliferation in premenopausal women. Hum Reprod 9(11): 1991–1996

    PubMed  CAS  Google Scholar 

  • Ueki M, Okamoto Y, Tsurunaga T, Seiki Y, Ueda M, Sugimoto O (1995) Endocrinological and histological changes after treatment of uterine leiomyomas with danazol or buserelin. J Obstet Gynaecol 21(1): 1–7

    CAS  Google Scholar 

  • Wade GN, Powers JB, Blaustein JD, Green DE (1993) ICI 182,780 antagonizes the effects of estradiol an estrous behavior and energy balance in Syrian hamsters. Am J Physiol 265: R1399–1403

    PubMed  CAS  Google Scholar 

  • Wakeling AE, Bowler J (1992) ICI 182,780, a new antioestrogen with clinical potential. J Steroid Biochem Mol Biol 43(1–3): 173–177

    Article  PubMed  CAS  Google Scholar 

  • Yan H, Wang J (1994) The clinical study an hysteromyoma treated with acupuncture. Zhen Ci Yan Jiu 19: 14–16

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. F. H. Gauwerky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Djavadian
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Frauenklinik, Amper-Kliniken AG, Konrad-Adenauer-Str. 30, 85221, Dachau, Germany

    Johannes F. H. Gauwerky

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Gauwerky, J.F.H., Djavadian, D. (2003). Medikamentöse Behandlung des Uterus myomatosus. In: Gauwerky, J.F.H. (eds) Uterus myomatosus. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55907-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-55907-5_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63139-9

  • Online ISBN: 978-3-642-55907-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation